Ridge Diagnostics, Inc.
Presents Clinical Data on Blood Test for Depression at
68th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry

----

San Diego, CA May 15, 2013 – Ridge Diagnostics, Inc., a neurodiagnostic company, announced that the latest data from a clinical study for its first-in-class, proprietary MDDScore™ blood test for Major Depressive Disorder (MDD) will be presented at the 68th Annual Scientific Convention and Meeting of the Society of Biological Psychiatry in San Francisco, CA, May 16th - 18th, during a poster session entitled: *A Biomarker Panel and Gender Specific Algorithms to Aid in Diagnosis of Major Depressive Disorder.*

For the first time, a blood test has been developed, MDDScore, which provides psychiatrists with biological information derived from physiological changes associated with MDD.   With a biological basis, the quantitative blood test results are intended to augment the Standardized Diagnostic Interviews (SDI) used for neuropsychiatric diagnosis and patient management.

The Ridge poster illustrates and articulates a biomarker panel which was developed as an aid to MDD diagnosis. It consists of nine biomarkers associated with the neurotrophic, metabolic, inflammatory and HPA systemic pathways and a proprietary algorithm. The poster discusses the performance of the test using serum levels of nine biomarkers in peripheral blood measured by individual quantitative immunoassays. In addition, the panel performance was enhanced by including gender and body mass index (BMI). The overall study outcomes yielded results of 94% sensitivity, 92% specificity and an area under curve (AUC) of 0.96.

 "We are pleased to report significant and enhanced findings from our recent clinical studies to the psychiatric community at the Annual Scientific Convention and Meeting of the Society of Biological Psychiatry. MDDScore's latest results were over 90% accurate when gender and BMI were added to Ridge's proprietary algorithm," stated Lonna J. Williams, CEO of Ridge Diagnostics.

The poster will be presented by Dr. John Bilello, Chief Scientific Officer of Ridge Diagnostics, on Thursday, May 16th.

"The biology of depression suggests that a highly complex series of interactions exists between the brain and biomarkers in peripheral circulation. Given the complexity and variability of these types of disorders and the associated biomarkers in an individual, it is easy to understand why approaches measuring a single factor would not have sufficient clinical utility," says study co-author, John Biello, PhD.

Ridge Diagnostics, Inc. Ridge Diagnostics is a neurodiagnostic company developing and marketing blood-based tests to diagnose and monitor neuropsychiatric disorders. Ridge has commercialized the first-in-class, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD).   The portfolio of neurodiagnostic blood tests are based on a proprietary Human Biomarker Library and technology platform. The testing services are provided by the Ridge owned CLIA laboratory. The company is located in San Diego, CA and Research Triangle Park, NC.

Contacts:

Investor Relations: Media Relations
Lonna J Williams, CEO   Debora I. Demarest, Director, Corporate Communications
800-578-7818 ex 101   800-578-7818 ex 106
lwilliams@ridgedx.com   ddemarest@ridgedx.com